$1.13
-0.03-3.02%
At close: -
$1.22
0.098.44%
After Hours: Mar 28, 8:48 AM EDT
Comments
Loading...
XTL Biopharmaceuticals Analyst Ratings and Price Targets | NASDAQ:XTLB | Benzinga
XTL Biopharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for XTL Biopharmaceuticals Corp from these most-recent analyst ratings.
Analyst Ratings for XTL Biopharmaceuticals
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for XTL Biopharmaceuticals (XTLB) stock?
There is no price target for XTL Biopharmaceuticals
What is the most recent analyst rating for XTL Biopharmaceuticals (XTLB)?
There is no analyst for XTL Biopharmaceuticals
When was the last upgrade for XTL Biopharmaceuticals (XTLB)?
There is no last upgrade for XTL Biopharmaceuticals
When was the last downgrade for XTL Biopharmaceuticals (XTLB)?
There is no last downgrade for XTL Biopharmaceuticals.
When is the next analyst rating going to be posted or updated for XTL Biopharmaceuticals (XTLB)?
There is no next analyst rating for XTL Biopharmaceuticals.
Is the Analyst Rating XTL Biopharmaceuticals (XTLB) correct?
There is no next analyst rating for XTL Biopharmaceuticals.
Browse analyst ratings and price targets on all stocks.